Positive trial results for Kodiak Sciences Inc’s eye drug could sustain momentum as stocks have been trading up by 171.09 percent
Click Here for a Millionaire's POV on Trading KOD
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- UBS reaffirms its Buy on Kodiak Sciences, calling for non-inferior phase III wet AMD data versus Eylea and slapping an $80 target on KOD, far above the recent ~$31 level.
- Goldman Sachs restarts coverage on Kodiak Sciences with a Neutral and a $36 target, tying KOD to improving biotech sentiment driven by M&A, clinical wins, and friendlier regulators.
- Pivotal Phase 3 DAYBREAK topline results for Zenkuda (tarcocimab) and KSI-501 in wet AMD hit on 2026/09/28, putting Kodiak Sciences in the spotlight.
- Management has also laid out timelines for more Phase 3 retina readouts in 2026, turning KOD into a catalyst-heavy biotech trading vehicle.
Live Update At 12:33:00 EDT: On Monday, September 28, 2026 Kodiak Sciences Inc stock [NASDAQ: KOD] is trending up by 171.09%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
KOD is trading like a classic binary-event biotech. For most of September, Kodiak Sciences chopped around the low- to mid-$30s, with closes between roughly $31 and $36. Then, on 2026/09/28, the tape changed completely. KOD opened near $61.70 and finished the day around $87.70, after spiking as high as $89.69. That is a massive, high-volume re-pricing in a single session.
Intraday, the 5‑minute chart shows exactly what aggressive momentum looks like. Kodiak Sciences ripped from the low $60s at the open into the high $80s, with repeated consolidation-and-rip patterns all morning. Dips were brief and bought, which tells traders algos and momentum funds were leaning long into the catalyst.
More Breaking News
- VWAV Stock Slides After Parabolic Run As Traders Reset
- GNRC Soars As Generac Wins Massive Amazon Data Center Deal
- GNRC Stock Soars As Amazon Data Center Deal Reprices Growth
- American Airlines Stock Grinds Higher As Traders Weigh Fuel Risks
Under the hood, KOD is still a money-burning clinical-stage story. For Q2 2026, Kodiak Sciences posted a net loss of about $65.6M, or roughly -$1.05 per share, driven mainly by heavy research spend of about $56.1M. Operating cash outflow of around $46.2M shows the burn is real. But Kodiak Sciences ended the quarter with roughly $132.1M in cash, plus a solid current ratio of 2.5, giving KOD some runway to get through these major readouts.
Why Traders Are Watching KOD Right Now
KOD is on every momentum trader’s screen because the story lines up perfectly with how this market trades catalysts. UBS reiterated a Buy rating on Kodiak Sciences and pinned an $80 price target on the stock when it was around $31. That is more than double upside, tied directly to what happens with the phase III wet AMD trials for Zenkuda (tarcocimab) and KSI-501.
UBS is not talking about a small tweak. They argue Kodiak Sciences has a real shot at showing non-inferiority to Eylea, the entrenched standard, with potentially longer dosing intervals. For traders, that means if KOD data confirms similar vision outcomes with fewer shots in the eye, the market may assign Kodiak Sciences real commercial value instead of just pipeline optionality. That’s the kind of narrative that can extend a squeeze.
At the same time, Goldman Sachs has stepped back in with a Neutral rating and a $36 target. That tells you big money is engaged but still treating Kodiak Sciences as a high-risk, event-driven name. KOD benefits from a strong biotech backdrop — M&A, clinical wins, and a more forgiving FDA — yet Goldman is reminding traders the story still lives and dies by trial results.
The calendar is packed. Kodiak Sciences has the DAYBREAK topline data on 2026/09/28, then additional readouts at AAO in October, and more data into December. That cluster of catalysts is why KOD is whipping around and why short-term traders are stalking every headline and every tick of the tape.
Conclusion
Right now, KOD is a textbook “catalyst plus chart” setup that active traders study for years. Kodiak Sciences has late-stage retina assets — Zenkuda and KSI-501 — sitting at the edge of pivotal Phase 3 DAYBREAK data, with more Phase 3 readouts lined up across 2026. UBS pounding the table with an $80 target, versus the old ~$31 area, shows how much upside the Street believes is on the table if results land as hoped.
On the other side, Goldman Sachs sitting at Neutral with a $36 target is the reality check. Kodiak Sciences is burning over $40M in cash per quarter, posting deep negative returns on equity and assets, and trading at a rich price-to-book multiple. KOD’s spike from the $30s to the high $80s in a single day makes sense only if traders accept this is a pure volatility play around binary clinical outcomes.
For active traders, the message is simple: respect the risk, but learn from the pattern. Multiple banks are focused on the same KOD catalysts, and the chart is screaming elevated expectations. In this kind of fast-moving, catalyst-driven ticker, tracking what works and what doesn’t becomes crucial. As Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.”. As Tim Sykes loves to say, “Volatility is opportunity, but only if you manage your risk and cut losses fast.” Kodiak Sciences is giving the market that volatility; how traders handle it will decide who survives the next big headline. This coverage is for educational and research purposes only, not trading advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.